Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

BACKGROUND: Immune checkpoint inhibitors (ICIs) has shown remarkable benefit in the treatment of a range of cancer types, although it may initiate immune related adverse events (irAEs) in patients. Some studies have shown that there is a close relationship between the occurrence of irAEs and prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoyun, Xu, Shuo, Wang, Jiaqi, Lv, Yalei, Wang, Na, Lai, Ruixue, Sha, Ziyue, Zhao, Qun, Guo, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636611/
https://www.ncbi.nlm.nih.gov/pubmed/36335320
http://dx.doi.org/10.1186/s12885-022-10199-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636611/
https://www.ncbi.nlm.nih.gov/pubmed/36335320
http://dx.doi.org/10.1186/s12885-022-10199-x

Ejemplares similares